CDx development
GenDx, OSE Immunotherapeutics Ink Deal to Develop NGS CDx for Epitope-Based Cancer Vaccine
Under the deal, GenDx will develop and validate a companion diagnostic test for high-resolution typing of HLA-A*02 based on its IVDR-registered NGS products.
Promega to Develop Microsatellite Instability Companion Diagnostic Kit With GlaxoSmithKline
The IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with GSK's Jemperli (dostarlimab-gxly).
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
Qiagen CDx for GI Cancer Treatment Ayvakit Gets FDA Approval
The test detects a mutation in a platelet-derived growth factor receptor gene that is associated with primary resistance to other treatments for gastrointestinal stromal tumors.
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.